1. Home
  2. LTRX vs ADAG Comparison

LTRX vs ADAG Comparison

Compare LTRX & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantronix Inc.

LTRX

Lantronix Inc.

HOLD

Current Price

$6.10

Market Cap

236.4M

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$3.64

Market Cap

260.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTRX
ADAG
Founded
1989
2011
Country
United States
China
Employees
352
N/A
Industry
Computer Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
236.4M
260.3M
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
LTRX
ADAG
Price
$6.10
$3.64
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$6.50
$8.25
AVG Volume (30 Days)
721.9K
253.5K
Earning Date
05-06-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$122,923,000.00
N/A
Revenue This Year
$1.12
N/A
Revenue Next Year
$15.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.86
$1.44
52 Week High
$8.75
$4.85

Technical Indicators

Market Signals
Indicator
LTRX
ADAG
Relative Strength Index (RSI) N/A 47.57
Support Level N/A $3.23
Resistance Level N/A $3.99
Average True Range (ATR) 0.00 0.28
MACD 0.00 0.01
Stochastic Oscillator 0.00 54.76

Price Performance

Historical Comparison
LTRX
ADAG

About LTRX Lantronix Inc.

Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: